



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 08-01-2011

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL
DESIGNS FOR THE WEEK-ENDING OF 24-12-2010 TO BE
PUBLISHED 11-01-2011 IN THE GAZETTE OF PAKISTAN PART-
V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

Sd/-
(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215056

ENCL: Thirty-one pages.

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

20-12-2010

1054/2010	Syngenta Participations AG Switzerland (Priority 22-12-2009 G.B.)	“Novel pyridazine derivatives”
1055/2010	Sanofi-Aventis France (Priority 21-12-2009 USA)	“Transgenic non-human animal and uses thereof”
1056/2010	Novartis AG Switzerland (Priority 21-12-2009 India)	“Diaza-spipo[5.5]undecanes”
1057/2010	Novartis AG Switzerland (Priority 23-12-2009 USA)	“Substituted isoquinolinones and quinazolinones”
1058/2010	Novartis AG Switzerland (Priority 22-12-2009 USA)	“Soluble proteins for use as therapeutics”
1059/2010	Plexxikon, Inc., USA (Priority 23-12-2009 USA)	“Compounds and methods for kinase modulation, and indications therefore”

21-12-2010

1060/2010	Lucite International uk Limited United Kingdom (Priority 21-12-2009 United Kingdom)	“Method of producing Acrylic and Methacrylic acid”
1061/2010	H. Lundbeck A/S Denmark (Priority 23-12-2009 USA)	“Processes for the manufacture of a pharmaceutically active agent”
1062/2010	Chiesi Farmaceutici S.P.A., Italy (Priority 23-12-2009 Europe)	“Aerosol formulation for COPD”
1063/2010	Chiesi Farmaceutici S.P.A., Italy (Priority 23-12-2009 Europe)	“Aerosol formulation for COPD”

1064/2010	Chiesi Farmaceutici S.P.A., Italy (Priority 23-12-2009 Europe)	“Combination therapy for COPD”
1065/2010	Chiesi Farmaceutici S.P.A., Italy (Priority 23-12-2009 Europe)	“Combination therapy for COPD”
1066/2010	Sanofi-Aventis France (Priority 23-12-2009 USA)	“Treatment for inflammatory bowel disease”
1067/2010	Sanofi-Aventis France (Priority 23-12-2009 USA)	“Tropinone benzylamines as beta-tryptase inhibitors”
1068/2010	Sanofi-Aventis France (Priority 23-12-2009 USA)	“Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof”
1069/2010	Takeda Pharmaceutical Company Limited Japan (Priority 22-12-2009 Japan)	“Sustained-release formulation”
1070/2010	Sanofi-Aventis France (Priority 23-12-2009 USA)	“[4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof”
1071/2010	Novartis AG Switzerland (Priority 23-12-2009 USA)	“Lipids, lipid compositions, and methods of using them”
1072/2010	Sanofi-Aventis France (Priority 23-12-2009 USA)	“Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors”

22-12-2010

1073/2010	Agrinos AS Norway (Priority 23-12-2009 USA)	“Biodegradation process and composition”
1074/2010	Bayer CropScience AG Germany (Priority 23-12-2009 Europe)	“Plants tolerant to hppd inhibitor herbicides”

1075/2010	Bayer CropScience AG Germany (Priority 23-12-2009 Europe)	“Plants tolerant to hppd inhibitor herbicides”
1076/2010	Bayer CropScience AG Germany (Priority 23-12-2009 Europe)	“Plants tolerant to HPPD inhibitor herbicides”
1077/2010	Bayer CropScience AG Germany (Priority 23-12-2009 Europe)	“Plants tolerant to HPPD inhibitor herbicides”
1078/2010	Bayer CropScience AG Germany (Priority 23-12-2009 Europe)	“Plants tolerant to HPPD inhibitor herbicides”
1079/010	Mitsubishi Heavy Industries , Limited Japan (Priority 06-08-2010 Japan)	“Aeration apparatus, seawater flue gas desulphurization apparatus including the same, and humidification method for aeration apparatus”
1080/2010	Takeda San Diego, Inc USA (Priority 23-12-2009 USA)	“Fused heteroaromatic pyrrolidinones”
1081/2010	Abbott Laboratories USA (Priority 23-12-2009 USA)	“Novel thienopyrrole compounds”
1082/2010	Abbott Laboratories USA (Priority 20-01-2010 USA)	“Methods for treating pain”

23-12-2010

1083/2010	Regeneron Pharmaceuticals, Inc. USA (Priority 24-12-2009 USA)	“Human antibodies to human angiopoietin-like protein 4”
1084/2010	Colourtex Industries Limited India (Priority 23-12-2009 India)	“Disperse azo dyes”
1085/2010	Colourtex Industries Limited India (Priority 23-12-2009 India)	“Disperse dyes”

24-12-2010

1086/2010 Hexima Limited
Australia
(Priority 05-08-2008 USA)
Divisional

“A genetically modified Plant or progeny thereof”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


226/1997 Novartis AG.,
Switzerland

"Heterocyclic azaheptane compound"

CO7D 277/10

141049

There is described a compound of formula I,



wherein

R₁ is lower alkoxy carbonyl,

R₂ is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,

R₃ is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C₄-C₈cycloalkyl,

R₄ is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen,

oxygen, sulfur, sulfinyl (-SO-) and sulfonyl (-SO₂-) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,

R₅, independently of R₂, has one of the meanings mentioned for R₂, and

R₆, independently of R₁, is lower alkoxy-carbonyl.

The compound is an inhibitor of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. It exhibits outstanding pharmacodynamic properties.

220/2005 Lubna Iqbal,
Dr. Kauser Siddique,
Dr. Yasar Saleen,
Dr. Husan Afroz Rizvi,
Dr. Mufti Asif Ullah,
PCSIR, Karachi,
Pakistan

“Process for the preparation of weight reducing dietary composition in powder form”

GO1N 33/02

141050

The process for the preparation of weight reducing dietary composition in powder form comprises of sifted soy meal, rice powder, skimmed milk, roasted at 75-100°C for 1-5 hrs and then mixed with agar agar, xanthan Gum, sorbitol, sodium cyclamate, saccharin, Vitamin C, Vitamin A&D, flavor and Sodium Benzoate in a rotary mixer till homogeneity before packaging 30 g in aluminum foil sachet under sterile and inert (nitrogen) condition with the shelf life of 24 months.

676/2005 E.I.Du Pont De Nemours and
Company,
USA


“A composition comprising an anthranilamide invertebrate pest control agent”

AO1N 43/56, AO1P 7/00

141051

Disclosed are mixture and composition for controlling invertebrate pest relating to combinations comprising (a) 3-bromo-N-[4-cyano-2-methyl-6-

[(methylamino)carbonyl]phenyl]- 1 -(3 - chloro-2-pyridiny1)- 1H-pyrazole-5-carboxamide, an N-oxide, or a salt thereof,



and

(b) at least one invertebrate pest control agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondria' electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and salts of the foregoing.

Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.

703/2005

Lurgi Zimmer GmbH,
Germany

“Method for manufacturing polyethylene terephthalate containing low amounts of diethylene glycol in the presence of monocarboxylic acid”

CO8G 63/81

141052

A method is described for the manufacture of polyethylene terephthalate from terephthalic acid and

ethylene glycol in the presence of a monocarboxylic acid, which comprises the steps of: (a) in a first reaction step, esterifying a saturated solution of terephthalic acid with ethylene glycol in a mixture of a monocarboxylic acid with water or another suitable solvent to obtain as an intermediate a monoethylene glycol terephthalate carboxylate, a diethylene glycol terephthalate carboxylate, or oligomers thereof, wherein the ethylene glycol is employed in a molar amount equal to or less than the sum of the molar amounts of terephthalic acid and monocarboxylic acid together; and (b) in a second reaction step, converting the monoethylene glycol terephthalate carboxylate or the diethylene glycol terephthalate carboxylate, or the oligomers thereof to polyethylene terephthalate containing less than 0.1% by weight of diethylene glycol.


431/2006 N.V. Organon,
Netherlands

“A 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline compound and pharmaceutical composition containing it.”

A61K 31/47, A61K 31/4709, A61P 5/24, CO7D 215/20, CO7D 401/12

141053

The present invention relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline having the general formula I,



wherein R¹ is (1-6C)alkyl, (2-6C)alkenyl or (2-6C)alkynyl; R² is halogen; R³ is SO₂NR⁵R⁶ or (1-4C)alkoxy, optionally substituted with one or more fluor atoms;

X is 0 or NR⁷; R⁴ is R⁸-(2-8C)alkyl, R⁸-(3-8C)alkenyl, R⁸-(3-8C)alkynyl or R⁸-(2-4C)-alkoxy(2-4C)alkyl; Z is CN or NO₂; R⁵ and R⁶ are independently H or (1-4C)alkyl; or R⁵ together with R⁶ and the N to which they are bonded form a 3-8 membered saturated ring optionally containing a further heteroatom selected from O and S; R⁸ is OH, (1-4C)alkoxy, NH₂; NR⁹C(0)R¹¹, NR⁹SO₂R¹¹ or C(0)NR⁹R¹⁰; R⁷ and R⁹ are independently H or (1-4C)alkyl; R¹⁰ is (1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, or phenyl(1-4C)alkyl or (2-5C)heteroaryl(1-4C)alkyl, both optionally substituted on the (hetero)aromatic ring with one or more substituents selected from OH, NH₂, halogen, NO₂, CF₃, CN, (1-4C)alkyl, (1-4C)alkoxy and (di)(1-4C)alkylamino; R¹¹ is (1-4C)-alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy(1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)alkoxy, (di)(1-4C)alkylamino, or phenyl or (2-5C)heteroaryl, both optionally substituted on the (hetero)aromatic ring with one or more substituents selected from OH, NH₂, halogen, NO₂, CF₃, CN, (1-4C)alkyl, (1-4C)alkoxy and (di)(1-4C)alkylamino; the invention also relates to pharmaceutical compositions comprising said derivative, as well as to the use of these 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives in therapy, more specifically for the treatment of fertility disorders.

439/2006


Daiichi Pharmaceutical Co.,
Ltd.,
Japan

“Tri-, tetra-substituted-3-aminopyrrolidine compound”


A61P 31/00

141054

A quinolone antibacterial compound, composition and a therapeutic compound for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by following formula (I):



wherein R^1 and R^2 represent hydrogen atom, or the like; R^3 represents an alkyl group containing 1 to 6 carbon atoms, or the like; R^4 and R^5 independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like, with the proviso that R^4 and R^5 do not simultaneously represent hydrogen atom; or the substituents R^4 and R^5 together represent (a) a 3- to 6-membered cyclic structure including the carbon atom shared by R^4 and R^5 to form a spirocyclic structure with the pyrrolidine ring; R^6 and R^7 independently represents hydrogen atom, an alkyl group containing 1 to 6 carbon atoms, or the like; R^6 represents a halogen-substituted alkyl group containing 1 to 6 carbon atoms, or the like; X^1 represents hydrogen atom or a halogen atom; A represents nitrogen atom or a moiety represented by formula (II):



1601/2006


N.V. Organon,
Netherlands

“Isoquinoline compounds”

CO7D 401/12, A61K 31/47

141055

The invention relates to isoquinoline compound having the general Formula I



wherein X is O, S or NH; Y is OH or NH₂; m is 0, 1 or 2; n is 1 or 2; R₁ is H, when Y is NH₂; or R₁ is H, (C₁₋₄)alkyl or halogen, when Y is OH; R₂ and R₃ are independently H, (C₁₋₄)alkyl or halogen; R is H or (C₁₋₆)alkyl, optionally substituted with OH, (C₁₋₄)alkyloxy, (C₁₋₄)alkyloxycarbonyl, (C₃₋₇)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C₆₋₁₀)aryl, (C₆₋₁₀)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C₁₋₄)alkyl, (C₁₋₄)alkyloxy, (C₁₋₄)alkylsulfonyl and halogen; or to pharmaceutical composition.

comprising the same as well as to the use of the isoquinoline compound in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.

600/2007

Vestergaard Frandsen S.A.,
Switzerland

"System for tracing refugee shelters by a satellite"

141056

A system for tracing a refugee shelter having an upper surface of which one part is white and the other part is green in order to be more pronounced for satellite recognition. A satellite is configured to image the surface of the earth with multi colour camera for investigation with an image analysis system configured to analyse images with respect to objects having a green part and a white part, each part having a size equal to or larger than the resolution of the camera.




Fig.05

702/2007

Honda Motor Co., Ltd.,
Japan“Battery mounting structural body for a
motorcycle”


B62K 11, HO1M 2/10

141057

To provide a battery mounting structural body that facilitates disconnection of positive and negative electrode terminals in correct order when battery electrode terminals or a power cable is disconnected. [Solving Means]

A battery mounting structural body includes: a battery 30 including a positive electrode side terminal 52 and a negative electrode side terminal 42; a

positive electrode side cable 50 connected to the positive electrode side terminal 52 via a connector bracket 51; a protective cover 54 covering, from above, the positive electrode side terminal 52 to which the positive electrode side cable 50 is connected; a negative electrode side cable 40 having a first end side connected to the negative electrode side terminal 42 via a connector bracket 41 and a second end side grounded to a vehicle body side; and a lid member 37 disposed upward of, and to be close at least to, the protective cover 54 when the battery 30 is mounted in a predetermined position. The lid member 37 is fixed to a holder 31 that accommodates the battery 30. The battery 30 is mounted in the predetermined position when a holding band 33 is closed. The presence of the lid member 37 prompts removal of the negative electrode side first.



127/2008

Vestergaard Frandsen S.A.
Switzerland

“Process and composition for synergistically enhanced insecticidal impregnation of a fabric or netting or other kind of non-living material”

AO1N 25/34

141058

A non living insecticidal material is provided, for example a fabric or netting, with a polymeric matrix into which at least one synergist is migratably incorporated before a coating

with a film containing at least one insecticide.

163/2008 Bil Care Limited,
India

“A personalized healthcare management system”

B65D 83/04, G06Q 50/00

141059

The present invention provides a personalized integrated healthcare anticounterfeit management method and a system capable of pack authentication, user feedback and compliance, documentation of the dosage uptake by the users, maintenance of user related data and displaying compliance and feedback information, liaising with various healthcare agencies, users' nominated persons / medical practitioner, providing real-time and authentic data in raw and analysed form to diverse agencies in the healthcare chain. An integrated healthcare management system relating to a patient which is interactive between a first healthcare agency and at least one other party, the said other party being selected from the patient and at least one other healthcare agency is provided. The system comprises of patient medication system comprising a package comprising a product for dispensing, information relating to the identity of the package and the patient medication system being communicably linked to the remote system.

307/2008 Linda Muller,
Switzerland

“Method for manufacturing a waterproof and vapor-premeable shoe and shoe obtained with the method”

A43B 7/12, A43B 9/08

141060

A method for manufacturing a

waterproof and vapor-permeable shoe, consisting in preparing a semimanufactured component of an upper (12) for a shoe, such that it can be arranged spread out on a flat surface or on two mutually opposite surfaces, then arranging on the inner part of the semimanufactured component of an upper (12) a waterproof and vapor-permeable membrane (13), then preparing means for adhesive bonding between the semimanufactured component of an upper (12) and the membrane (13) so as to not inhibit the vapor-permeability of the assembly. One or more shapes, which are substantially flat but capable of shaping themselves complementarily with respect to the different thicknesses of the stitched seams and of the superimposed parts which constitute the outer surface of the semimanufactured component of an upper (12) are then prepared, and the membrane (13) is then coupled to the semimanufactured component of an upper (12), with the outer part of the semimanufactured component arranged so that the outer surface rests on the shape. The upper (12) is then finished by making it assume the correct three-dimensional configuration and associating it with an insole (14), and finally a sole (16) is associated with the upper (12) and the insole (14).

665/2008

AstraZeneca AB,
Sweden


“Substituted N-(1-(thiazol-2-yl)piperidin-4-yl)-1H-pyrrole-2-carboxamide Compound”

CO7D 417//08, CO7D 417/00

141061

The invention relates to substituted N-(1-(thiazol-2-yl)piperidin-4-yl)-1H-pyrrole-2-carboxamide compound useful for the treatment of bacterial infections in warm-blooded animals,

such as humans. The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. Therefore, novel antibacterial compound suitable for pharmaceutical administration are necessary. Accordingly, compound of formula (I) useful in the treatment of bacterial infections are described.



767/2008

Vestergaard Frandsen S.A.,
Switzerland

“An insecticidal barrier of a non-living material”

AO1M 29/00

141062

An insecticidal barrier of a non-living material comprising a first region and a second region, wherein the first region comprises a synergist and the second region comprises an insecticide but no synergist.

1528/2008

ENI S.P.A.,
Italy
Institut Francais Du Petrole,
France

“Process for stabilizing the performance of a catalyst for fischer tropsch reaction”

BO1J 21/00

141063

Process for maintaining the stability of performances of a catalyst for Fischer-Tropsch reaction, performed in a slurry bubble column reactor under a triphase system, which comprises gradually

increasing the P_{H20}/P_{H2} ratio and the P_{H20}/Z ratio, during the start-up phase, with $Z = P^O \cdot (T/T_1)^4 \cdot e^{-(K2/(t \cdot K3))}$ from 0.4 to 0.8, for a period of time not shorter than 100-150 hrs and not longer than 200-300 hours and, at the end of the start-up phase, maintaining the P_{H20}/P_{H2} and P_{H20}/Z ratios substantially equal to or lower than 0.8.

235/2009
 Commerzialbank Mattersburg
 im Burgenland
 Aktiengesellschaft,
 Austria

“Method for production of an oil-binding agent”

CO9K 3/32

141064

Method for production of an oil-binding agent, using highly porous natural silicate material and residue containing organic matter, in which the highly porous natural silicate material, with an initial particle size between 4 and 10 mm, is mixed with the residue containing organic matter, the mixture is calcined at a temperature between 520 and 550°C and then ground to a particle size spectrum essentially between 4 and 0.125 mm.


717/2009
 Novartis AG.,
 Switzerland

“A salt of a heterocyclic azahexane compound”

CO7D 277/10

141065

There is described a salt of a compound of formula I,



wherein

R₁ is lower alkoxy-carbonyl,
R₂ is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,
R₃ is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C₄-C₈cycloalkyl,
R₄ is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (-SO-) and sulfonyl (-SO₂-) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,
R₅, independently of R₂, has one of the meanings mentioned for R₂, and
R₆, independently of R₁, is lower alkoxy-carbonyl.

The salt of a compound is an inhibitor of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. It exhibits outstanding pharmacodynamic properties.

832/2009 Rijksuniversiteit Groningen,
Netherlands

“An aqueous formulation comprising oxytocin or vasopressin and a non-toxic source of divalent metal ions”

A6K 38/11

141066

The present invention relates to the field of preventive and therapeutic medicine, in particular to peptide formulations. Provided is a pH-buffered aqueous formulation comprising oxytocin, vasopressin or an analogue thereof and at least one non-toxic source of divalent metal ions in a concentration of at least 2 mM, and the use of the formulation for the manufacture of a medicament for therapeutic and/or prophylactic treatments.

80/2010

Otsuka Pharmaceutical
Factory Inc.,
Japan


“Phenylimidazole compound”

A61K 31/4164

141067

To provide a pharmaceutical product (chemotherapeutic agent) effective in the prevention and treatment of hyperlipidemia, obesity, etc.

[Solving Means] A phenylimidazole compound represented by the following General Formula (1):



wherein, R¹ represents a hydrogen atom, a phenyl lower alkyl group optionally having a substituent, or a pyridyl lower alkyl group optionally having a substituent, and the benzene ring and the pyridine ring are optionally substituted with 1 or 2 substituents selected from the group consisting of halogen atoms, cyano group and halogen-substituted lower alkyl groups. One of R² and R³ represents a hydrogen atom and the other represents a lower alkoxy group. R⁴ represents a phenyl group optionally having a substituent. R⁸ and R⁶ are the same or different, and represent a hydrogen atom or a lower alkyl group. R⁷ and R⁸ are the same or different, and represent a hydrogen atom or a lower alkoxy group. However, when R¹ represents an unsubstituted phenyl lower alkyl group, R² represents a lower alkoxy group, R³ represents a hydrogen atom, R⁴ represents a phenyl group optionally having a substituent, and R⁸ represents a hydrogen atom, R⁶ is not a hydrogen atom.

414/2010


Clariant International Ltd.,
Switzerland

“A process for the production of tanned leather, skins or pelts by non-metal tanning and an aqueous tanning composition”

C14C 3/26

141068

Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning with a tanning agent (A) of formula (I),



(I)

wherein

Hal signifies fluorine or chlorine,

R1 signifies hydrogen, C₁₋₈-alkyl or an alkyleneoxy radical of formula (Ia),

R2 signifies C₁₋₄-alkyl or C₁₋₄-alkoxy,

m signifies 1 or 2,

n signifies 0 or 1,

q is of from 1 to 10,

M signifies hydrogen or an alkali metal cation or an ammonium cation,

in a tanning bath, the tanning bath having a pH of from 6 to 10 at the beginning of tanning step,

the invention relates to the defined tanning process, particular tanning agent compositions, the use of the tanned leather, skins or pelts for further processing and the produced tanned and optionally further processed leather, skins or pelts.

963/2010


AstraZeneca AB.,
Sweden

"A pharmaceutically acceptable salt substituted N-(1-(thiazol-2-yl)piperidin-4-yl)-1H-pyrrole-2-carboxamide Compound"

CO7D 27/10

141069

The invention relates to a pharmaceutically acceptable salt of substituted N-(1-(thiazol-2-yl)piperidin-4-yl)-1H-pyrrole-2-carboxamide compound useful for the treatment of bacterial infections in warm-blooded animals, such as humans. The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. Therefore, novel antibacterial compounds suitable for pharmaceutical administration are necessary. Accordingly, compounds of formula (I) useful in the treatment of bacterial infections are described.



**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.**140135** Ante date: **03-02-1999** Priority.date.**05-02-1998** (**U.K**)
Granted to:- **SMITHKLINE BEECHAM BIOLOGICALS (S.A.)** a Belgium company of
Rue de l'institut 89, B-1330 Rixensart, Belgium

In pursuance of an application received on **22-09-2010** the following entry has been made
in the register of patents the Name of the patentee has been changed to:- **GlaxoSmithKline
Biologicals SA**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.138215 date: **11-09-2002** Priority.date.**13-09-2000** (GB) granted to:- **SMITHKLINE BEECHAM PLC** (a company duly incorporated and existing under the laws of England), of **980 Great West Road, Brentford, Middlesex TW8 9GS** England.

In pursuance of an application received on **20-09-2010** the following entry has been made in the register of patents the Name of the patentee has been changed to:- **SMITHKLINE BEECHAM LIMITED.**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.140838 date: 27-04-2010 Ante date: 11-09-2002
Priority.date.13-09-2001 (GB) granted to:- SMITHKLINE BEECHAM PLC (a
company duly incorporated and existing under the laws of England), of 980 Great
West Road, Brentford, Middlesex TW8 9GS England.

In pursuance of an application received on 20-09-2010 the following entry has been made
in the register of patents the Name of the patentee has been changed to:- SMITHKLINE
BEECHAM LIMITED.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.140837 date: **11-09-2002** Priority.date.**13-09-2001** (GB) granted to:- **SMITHKLINE BEECHAM PLC** (a company duly incorporated and existing under the laws of England), of **980 Great West Road, Brentford, Middlesex TW8 9GS** England.

In pursuance of an application received on **20-09-2010** the following entry has been made in the register of patents the Name of the patentee has been changed to:- **SMITHKLINE BEECHAM LIMITED.**

**Registration of Assignment under Section 55(2) Rule 37(b) of the
Patent Ordinance 2000**

In the matter of patent No. 138016 dated 26-11-2001 Priority date 18-11-2000 (UK) Granted to: **Pharmacia & Upjohn S.P.A of Via Robert Koch 1.2, 20152 Milano, Italy.**

In pursuance of an application received on 22-11-2008

The following entry has been made in the Register of patents:- **NERVIANO MEDICAL SCIENCES SRL con sede in Viale Pasteur, 10-20014 Nerviano (Milano), Italia.** as Proprietor by virtue of Deed of Assignment dated **31-05-2010** made between **Phormacia & Upjohn SPA** as Assignor of the ONE PART and **Nerviano Medical Sciences SRL** as Assignee of the OTHER PART.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.**140125** date: **03-02-1999** Priority.date.**05-02-1998** (U.K)
Granted to:- **SMITHKLINE BEECHAM BIOLOGICALS (S.A.)** a Belgium company of
Rue de l'institut 89, B-1330 Rixensart, Belgium

In pursuance of an application received on **17-09-2010** the following entry has been made
in the register of patents the Name of the patentee has been changed to:- **GlaxoSmithKline
Biologicals SA**

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME IN
THE REGISTER OF PATENTS.**

In the matter of patent No.**139727** date: **12-02-2005** Priority.date.**14-02-2004** (UK) granted to:- **SMITHKLINE BEECHAM CORPPORATION** (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America), of One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America.

In pursuance of an application received on **10-08-2010** the following entry has been made in the register of patents the Name of the patentee has been changed to:- **GLAXOSMITHKLINE LLC** (a registered office in the state of Delaware), of Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, County of New Castle, Delaware 19808, USA.

**PROCEEDING UNDER SECTION 54(1) RULE 36(1) FOR CHANGE OF NAME
IN THE REGISTER OF PATENTS**

In the matter of patent No.**139730** date: **30-01-2008** Priority.date.**14-02-2004** (UK) granted to:- **SMITHKLINE BEECHAM CORPPORATION** (a corporation organized under the laws of the Commonwealth of Pennsylvania, one of the United States of America), of One Franklin Plaza, P.O. Box 7929, Philadelphia, Pennsylvania 19101, United States of America.

In pursuance of an application received on **10-08-2010** the following entry has been made in the register of patents the Name of the patentee has been changed to:- **GLAXOSMITHKLINE LLC** (a registered office in the state of Delaware), of Corporation Service Company 2711 Centerville Road, Suite 400, Wilmington, County of New Castle, Delaware 19808, USA.

NOTIFICATION

PROCEEDING UNDER SECTION. 42 OF THE ORDINANCE

Any person may give notice of opposition to the amendment proposed in the under mentioned Patent No. 138744 dated 09-02-2004 Priority Dated 10-02-2003 (U.S.A) by lodging Form 7, of Patent Rules 2003 together with the prescribed fee of Rs. 750/- at any time within two months from the date of advertisement in the Gazette, at the Patent office, 2nd Floor Kandawala Building M.A.Jinnah Road Karachi.

ELAN PHARMACEUTICALS, INC., corporation organized under the laws of California, United States of America of 800 Gateway Boulevard South San Francisco, United States of America.

SEEK TO AMEND THE Name of inventor of Mr. Christopher Phillips above for invention entitled "A stable, aqueous pharmaceutical composition comprising an immunoglobulin, a phosphate buffer, a polysorbate, and sodium chloride and method of preparation thereof" The proposed amendment is desired by way of correction.

The proposed amendment may be inspected in the Patent office.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>20-12-2010</u>			
1)	15094	Hot Pots (Class-03)	Shoaibee Industries
2)	15095	Hot Pots (Class-03)	Shoaibee Industries
3)	15096	Biscuit (Class-)	M/s. M.A. Food Industries (Pvt.) Ltd
4)	15097	Biscuit (Class-)	M/s. M.A. Food Industries (Pvt.) Ltd
<u>23-12-2010</u>			
5)	15098	Plastic Bottle (Class-03)	Abdur Rehman S/o Anis Ur Rehman

Sd/-
(SABIR GUL)
Controller of Patents
& Registrar of Designs
Ph: 99215056